🟢 C4 Therapeutics Inc is trading 5.2% up today as company presents positive Phase 1 cemsidomide data

C4 Therapeutics Inc is trading 5.2% up today at $4.04 following the presentation of positive Phase 1 data for its cemsidomide drug at the European Hematology Association (EHA) 2026 Congress.

• The data highlighted cemsidomide as a potential best-in-class IKZF1/3 degrader for multiple myeloma.
• At the 100 µg recommended Phase 2 dose, cemsidomide demonstrated a 53% overall response rate, including complete responses and MRD-negative status.
• The company also advanced multiple myeloma degrader cemsidomide with ongoing Phase 2 MOMENTUM and Phase 1b elranatamab combination trials.